8-K: Xencor Reports Positive Phase 1 Results for XmAb942 and Provides First Quarter 2025 Financial Update

Xencor announces positive interim Phase 1 results for XmAb942, supporting a 12-week maintenance dosing interval for ulcerative colitis treatment, and reports its first quarter 2025 financial results.

Summary

• Xencor reported its first quarter 2025 financial results on May 7, 2025.
• Interim Phase 1 results for XmAb942 support a 12-week maintenance dosing interval in the Phase 2b XENITH-UC study for ulcerative colitis, which is expected to begin in the second half of 2025.
• Nancy Valente, Executive Vice President and Chief Development Officer, will transition to a senior advisory role in June 2025.
• Xencor anticipates initiating first-in-human studies for an XmAb TL1A x IL23p19 bispecific antibody candidate during 2026.
• Incyte's supplemental Biologics License Application for tafasitamab was accepted for review by the U.S. Food and Drug Administration in February 2025, resulting in a $12.5 million regulatory milestone payment for Xencor.
• Vir Biotechnology initiated a Phase 3 study of tobevibart in combination for people living with CHD in March 2025, resulting in a $2.0 million development milestone payment for Xencor.
• Todd Simpson was appointed to Xencor's board of directors in March 2025.
• Xencor expects to end 2025 with between $535 million and $585 million in cash, cash equivalents, and marketable debt securities, funding operations into 2028.
• Cash, cash equivalents, and marketable debt securities totaled $693.5 million as of March 31, 2025, compared to $706.7 million as of December 31, 2024.
• Revenue for the first quarter of 2025 was $32.7 million, compared to $16.0 million for the same period in 2024.
• Research and development expenses for the first quarter of 2025 were $58.6 million, compared to $56.9 million for the same period in 2024.
• General and administrative expenses for the first quarter of 2025 were $17.3 million, compared to $13.8 million for the same period in 2024.
• Net loss attributable to Xencor for the first quarter of 2025 was $48.4 million, or $(0.66) per share, compared to a net loss of $73.4 million, or $(1.20) per share, for the same period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial results, increased revenue, and a strong cash position, although there are some concerns regarding the departure of a key executive and ongoing net losses.

Positives

• XmAb942 shows promise with interim Phase 1 results supporting a convenient 12-week dosing interval.
• The Phase 2b XENITH-UC study of XmAb942 is expected to start in the second half of 2025.
• Xencor is advancing an XmAb TL1A x IL23p19 bispecific antibody candidate into Phase 1 studies in 2026.
• Xencor received a $12.5 million regulatory milestone payment from Incyte.
• Xencor received a $2.0 million development milestone payment from Vir Biotechnology.
• Xencor's cash position remains strong, expected to fund operations into 2028.
• Revenue increased significantly in the first quarter of 2025 compared to the same period in 2024.

Negatives

• Nancy Valente, Executive Vice President and Chief Development Officer, is resigning from her role, although she will remain as a senior advisor.
• Xencor reported a net loss of $48.4 million for the first quarter of 2025, although this is an improvement compared to the $73.4 million loss in the same period in 2024.

Risks

• The development of biopharmaceutical products is inherently risky, and clinical trial data may not support continued development or regulatory approval.
• The loss of key members of management could negatively impact the company.
• Xencor's actual financial results may differ from its financial guidance.

Future Outlook

Xencor expects to end 2025 with between $535 million and $585 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that the company is on track to initiate the Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis later this year and expects to advance an XmAb TL1A x IL23p19 bispecific antibody candidate into Phase 1 in 2026.
• Dr. Dahiyat also thanked Nancy Valente for her contributions to Xencor as a Board member and CDO and expressed delight that she will remain active as a senior advisor.

Industry Context

Xencor is operating in the competitive biopharmaceutical industry, focusing on engineered antibodies for cancer and autoimmune diseases; the development of XmAb942 targeting TL1A for IBD positions them against other companies pursuing similar targets, with the potential for a more convenient dosing regimen.

Comparison to Industry Standards

• Xencor's XmAb technology aims to improve upon existing antibody therapies, such as first-generation anti-TL1A antibodies, by offering enhanced potency and extended half-life, potentially leading to more convenient dosing schedules.
• The development of bispecific antibodies like XmAb TL1A x IL23p19 reflects a broader industry trend towards multi-targeting therapies to address complex diseases more effectively.
• Compared to companies like Protagonist Therapeutics and Takeda, which are also developing therapies for ulcerative colitis, Xencor's XmAb942 aims to provide a differentiated profile with its extended half-life and convenient dosing.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical trial results and strong financial position.
• Employees may be affected by the management changes, but the company is ensuring a smooth transition.
• Patients with ulcerative colitis and other autoimmune diseases may benefit from the development of new therapies like XmAb942.

Next Steps

• Initiate the Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis in the second half of 2025.
• Advance an XmAb TL1A x IL23p19 bispecific antibody candidate into Phase 1 studies in 2026.
• Participate in upcoming investor conferences.

Key Dates

Keywords

Xencor, XmAb942, Ulcerative Colitis, TL1A, IL23p19, Bispecific Antibody, Incyte, Vir Biotechnology, Tafasitamab, Tobebivart, Financial Results, Clinical Trials, Antibody Engineering, Autoimmune Diseases, Cancer